As part of our series focussing on available medicines in Australia, we have added a product review of use of Empagliflozin for the management of patients with heart failure and preserved ejection fraction.
This review discusses heart failure with preserved ejection fraction, Australian guidelines, indications and dosage, contraindications and a series of clinical studies featuring Empagliflozin use. It also provides commentary from Associate Professor John Amerena, Cardiologist at Barwon Health.
Please login below to download this issue (PDF)